Drug Trial Radar · NCT06891885
A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Apr 16, 2026
Primary completion
Oct 31, 2028
Study completion Oct 31, 2032
Sponsor
- Lead sponsor
- Sumitomo Pharma America, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Goal of this study is to evaluate the safety, tolerability, and clinical responses following single dose of DSP-3077. Study enrolls both male and female patients in 3 cohorts with each cohort defined by visual acuity (VA) criteria and dose level of DSP-3077. Each cohort will include 4 participants.
Conditions
- Retinitis Pigmentosa
Interventions
DSP-3077 Retinal Sheet Cohort 1Drug
For each participant only 1 eye will receive a low dose (\>= 0.8 to \< 2.4 mm2) of single subretinal injection of DSP-3077 using the DSP-3077-delivery device on Day 1
DSP-3077 Retinal Sheet Cohort 2Drug
For each participant only 1 eye will receive a high dose (\>= 2.4 to \< 6.4 mm2) of single subretinal injection of DSP-3077 using the DSP-3077-delivery device on Day 1
DSP-3077 Retinal Sheet Cohort 3Drug
For each participant only 1 eye will receive a high dose (\>= 2.4 to \< 6.4 mm2) of single subretinal injection of DSP-3077 using the DSP-3077-delivery device on Day 1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of ocular adverse events (AEs)Time frame: 60 months
- Incidence of ocular serious adverse events (SAEs)Time frame: 60 months
- Incidence of ocular adverse events (AEs) leading to discontinuationTime frame: 60 months
- Incidence of adverse events (AEs)Time frame: 60 months
- Incidence of serious adverse events (SAEs)Time frame: 60 months
- Incidence of adverse events (AEs) leading to discontinuationTime frame: 60 months
- Incidence of adverse events (AEs) leading to deathTime frame: 60 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Massachusetts Eye and Ear
Boston, Massachusetts · Recruiting
University of Minnesota
Minneapolis, Minnesota · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.